Anonymous 01/24/2023 (Tue) 22:42 Id: 5100d0 No.118554 del
Ivermectin efficacy finally proven in ‘gold-standard’ RCT – Prof Colleen Aldous
23rd January 2023 by Nadya Swart

Another large randomised control study on ivermectin efficacy for preventing and treating COVID-19 has been released to the public ahead of publication in an academic journal. But unlike negative results trials, there has not been a big international splash across the mainstream media coordinated by a large publicity agency such as Bell Pottinger. Why? Because the results are undeniably positive, showing the efficacy of ivermectin in reducing infection after exposure by 72%, documented in a press release on Jan 5 2023(1).

This is the best quality RCT we have yet seen published on ivermectin. It is called the SAIVE Trial (NCT 05305560)(2) and is part of MedinCell’s research supporting their development of a novel slow-release form of ivermectin. Although sparse results have been released so far, the quality of the study is apparent. A total of 399 unvaccinated participants completed the study as per the protocol. The number intended for treatment is not available yet, but I anticipate that the only difference would be that the ITT number for the control group may have been 200. Those participants who received daily oral ivermectin showed a 72% reduction in COVID-19 infection compared to the control group.

The study was carried out in Bulgaria between March and November last year when we saw a global reduction of SARS-COV2 infections and a decrease in the severity of COVID-19. Vaccination could have been a confounding factor in the results, but the inclusion criterion of being unvaccinated accounted for that. It was a multi-centre study, which shows replicability to some degree, a central tenet of good science. It was a parallel-group, double-blinded, randomised and placebo-controlled study. There is little that can be done to improve the rigour of this study design. It was also overseen by a U.S.-based independent Data Monitoring Committee to ensure compliance and provide further quality assurance.